12:00 AM
 | 
Sep 11, 2000
 |  BioCentury  |  Emerging Company Profile

Calyx: Extracting compounds

Genomics may be the most recent drug discovery approach believed to represent a renewable source of therapeutic compounds, but the more conventional natural product approach has by no means been exhausted. In fact, Calyx Therapeutics Inc. believes it can find more than enough candidate compounds in botanical extracts with centuries of history as part of Ayurvedic medicine practices in India.

The company develops small molecule analogs of active ingredients from natural extracts that have shown clinical activity in humans. It has four lead compounds to treat diabetes, including CLX-0901, which is in Phase Ib testing, and two lead compounds to treat rheumatoid arthritis (RA) and other inflammatory disorders.

Calyx expects to have three compounds in the clinic by mid-2001,and at the moment does not intend to develop dietary supplements, focusing instead on regulatory approval of single compounds.

"First, we start out with an extract that has been used in Ayurvedic medicine in India for 100 years if not...

Read the full 780 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >